Orchid Pharma Limited
NSE: ORCHPHARMAMarket Closed • NSE
Day range
52 week range
Orchid Pharma Limited closed at INR911.25 (-1.81%) on volume 0.81x its 20-day average, trading 20.31% below its 52-week high.
2026-Q2
Q2 FY2026 Financial Results
PAT moved -87.5% QoQ
2023-08-02
AGM Announced
Annual General Meeting
2022-12-22
EGM Announced
Extra Ordinary General Meeting
Revenue and PAT bars use independent scales to make their year-on-year direction readable.
Complete reported financial history · Values use the company's reporting currency
Hover over the chart for exact reported values. Percentage lines use the right-hand axis.
A 0–100 quantitative summary of reported fundamentals. Use the underlying financials and risks for context; the score is not a buy or sell recommendation.
Strengths
Low Debt Profile: Debt-to-Equity is comfortable at 0.28x
High Cash Flow Conversion: CFO/PAT averaged 1.89x over last 3 years
Risks
Stretched Valuation: Trading at a high P/E multiple of 566.0x
Bull case
Market Leadership: Established operational scale in Drug Manufacturers - Specialty & Generic.
Bear case
Macro Headwinds: Fluctuations in interest rates and sector-specific policy shifts could compress multiples.
Flip condition
Sustained quarterly EBITDA margin expansion above 20% would trigger an upgrade.
Ownership distribution
Category trends
Hover over a period for exact holdings
Complete dividend, bonus, split, rights and other action history
| Record date | Corporate action | Information | Announcement date | Ex-date |
|---|---|---|---|---|
| — | Annual General Meeting | Annual General Meeting | — | 02 Aug 2023 |
| — | Extra Ordinary General Meeting | Extra Ordinary General Meeting | — | 22 Dec 2022 |
| — | Annual General Meeting | Annual General Meeting | — | 06 Jul 2022 |
| — | Annual General Meeting | Annual General Meeting | — | 04 Aug 2021 |
| — | Extra Ordinary General Meeting | Extra Ordinary General Meeting | — | 18 Jun 2021 |
| — | Annual General Meeting | Annual General Meeting | — | 21 Dec 2020 |
Traded volume and delivery percentage across the latest 20 sessions
Compare valuation, latest quarterly performance and year-on-year growth
| Company name | Market cap ₹ Cr | P/E ratio | Dividend yield % | Quarterly sales ₹ Cr | Profit after tax ₹ Cr | Sales growth % | Profit growth % |
|---|---|---|---|---|---|---|---|
 Sun Pharmaceutical Industries LimitedSUNPHARMA Open analysis | ₹4.22L | 34.90 | 0.91% | ₹15,300.00 | ₹2,901.00 | +10.46% | +26.52% |
 Divi's Laboratories LimitedDIVISLAB Open analysis | ₹2.43L | 82.97 | 0.33% | ₹3,080.00 | ₹902.00 | +27.80% | +65.50% |
 Torrent Pharmaceuticals LimitedTORNTPHARM Open analysis | ₹1.73L | 72.83 | 0.83% | ₹4,128.00 | ₹389.00 | +41.90% | -21.89% |
 Apollo Hospitals Enterprise LimitedAPOLLOHOSP Open analysis | ₹1.13L | 54.32 | 0.25% | ₹7,044.00 | ₹610.00 | +20.58% | +38.32% |
 Zydus Lifesciences LimitedZYDUSLIFE Open analysis | ₹1.12L | 25.03 | 0.09% | ₹8,017.00 | ₹990.00 | +21.95% | -34.91% |
 LENSKART SOLUTIONS LTDLENSKART Open analysis | ₹1.12L | 174.73 | 0.00% | ₹2,714.00 | ₹228.00 | +43.29% | +273.77% |
 Laurus Labs LimitedLAURUSLABS Open analysis | ₹1.11L | 101.83 | 0.12% | ₹2,026.31 | ₹367.60 | +29.10% | +125.49% |
 Cipla LimitedCIPLA Open analysis | ₹1.07L | 31.78 | 0.98% | ₹7,119.00 | ₹786.00 | +2.33% | -39.16% |
Orchid Pharma is a pharmaceutical company engaged in the development and manufacture of active pharmaceutical ingredients (APIs) and finished dosage forms. It is also engaged in research of new drugs. [1]
IndiaHealthcare
Is Orchid Pharma Limited Shariah compliant?
Orchid Pharma Limited is currently screened as Shariah Compliant under AAOIFI Shariah Standard No. 21. Business activities align with Shariah permissible sectors. Debt to Market Cap (7.85%) complies with AAOIFI threshold (≤ 33%).
What is Orchid Pharma Limited's current valuation relative to peers?
Orchid Pharma Limited trades at a P/E of 566.0x compared to the sector median of 37x, and a Price-to-Book of 3.6x.
Is the company financially healthy?
The company has a Debt-to-Equity ratio of 0.28x. Interest coverage is 12x.
What are the historical revenue and profit growth rates?
Over the past 5 years, revenue compounded at -0.2% while net profit growth averaged -25.9%.
Market data is informational and may be delayed. Shariah screening follows the displayed methodology. This is not investment advice.
Market data may be delayed. Quote date: 2026-10-16. Financial figures relate to their stated reporting periods. This information is for research and is not a recommendation to buy or sell.